Compare EW & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EW | BDX |
|---|---|---|
| Founded | 1958 | 1897 |
| Country | United States | United States |
| Employees | 16000 | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.3B | 54.6B |
| IPO Year | 1999 | 1998 |
| Metric | EW | BDX |
|---|---|---|
| Price | $90.30 | $195.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 30 | 16 |
| Target Price | $101.39 | ★ $195.57 |
| AVG Volume (30 Days) | ★ 3.1M | 1.4M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 2.11% |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.07 | ★ 1.59 |
| Revenue | $6,067,600,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $11.42 | N/A |
| Revenue Next Year | $9.91 | $2.34 |
| P/E Ratio | ★ $83.43 | $125.17 |
| Revenue Growth | ★ 11.55 | 8.24 |
| 52 Week Low | $74.66 | $140.11 |
| 52 Week High | $96.29 | $213.08 |
| Indicator | EW | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 60.19 | 62.19 |
| Support Level | $82.21 | $195.63 |
| Resistance Level | $93.43 | $213.08 |
| Average True Range (ATR) | 2.02 | 3.95 |
| MACD | 0.56 | 1.14 |
| Stochastic Oscillator | 93.62 | 78.74 |
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.